Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a full range of CD38 CAR-related products to aid in global customers’ CART projects. Feel free to explore and inquire about the specific product you need.
CD38 is a glycoprotein molecule with enzyme activity. As an enzyme, it has NAD-consumption and intracellular signaling activities, or cell adhesion receptor activity. CD38 is abundant on the surface of many immune cells, including B lymphocytes CD4+ lymphocytes, CD8+ lymphocytes, and natural killer cells. The role of CD38 is involved in several processes, including regulation of cell differentiation of immune cells, and effector function during inflammation. Studies have shown that CD38 plays an important role in the pathogenesis and prognosis of many diseases, such as multiple myeloma, chronic lymphocytic leukemia, and human immunodeficiency virus infection. And development of targeting CD38 CAR-T provides a promising solution for these diseases.
Fig.1 Scheme of CD38 CAR-T design.1
Anti-CD38 CAR-T Expression Test
The detection of CAR expression provides a reference for the evaluation of the transfection efficiency in the early stage of CAR-T development. Creative Biolabs has developed several robust and sensitive CAR detection reagents with different fluorescence labels to facilitate customers’ use. Meanwhile, we also provide a complete set of expression detection assays to evaluate target-specific CAR expression.
Fig.2 The CD38 CAR integration copy number detection of primary T cell after transduction by RT-qPCR.1
Anti-CD38 CAR-T Cell Proliferation Test
Creative Biolabs provides various CAR-T proliferation test services to evaluate the amplification capacity of CAR-T cells, such as carboxyfluorescein succinimidyl ester (CFSE)-based cell proliferation assay by flow cytometry to test the proliferation ability of CART cells when co-cultured with target cells.
Fig.3 Proliferation test of CD38 CAR-T cells by the CFSE-based methods.1
Phenotype Analysis of Anti-CD38 CAR-T Cell
To investigate the target-dependent activation and expansion of CAR-T cells, we have established a full list of testing services to assess the function of CAR-T cells, including the phenotype analysis by expression test of CD69, CD25, and HLA-DR.
Fig.4 The expression test of activation markers on CD38 CAR-T cells.2
Anti-CD38 CAR-T Cytokine Release Test
Creative Biolabs provides comprehensive cytokine analysis services to evaluate the cytokines-releasing capability of CART cells co-cultured with target cells, including but not limited to the following cytokines: TNFa, IFNg, IL-2, Granzyme B, IL-10, IL-6.
Fig.5 Cytokines secretion analysis of anti CD38 CAR-T cells co-cultured with RPMI-GFP-Luc target cells by CBA kit.1
Anti-CD38 CAR-T In Vitro Cytotoxicity Assay
Luciferase assay and lactate dehydrogenase (LDH) assay are extremely useful as a detection method to evaluate cell proliferation of CD38 CAR-T cells.
For in vitro tumor-killing tests, we offer a variety of approaches for customers to choose from:
Fig.6 In vitro tumor killing test of CD38 CAR-T cells against RPMI-GFP-Luc target cells or Raji-Luc target cells by luciferase assay.1
Fig.7 In vitro cytotoxicity assay of CD38 CAR-T cells against RPMI-GFP-Luc target cells at 1:1 E:T ratio measured by IncuCyte system.1
Fig.8 In vitro anti-tumor analysis of CD38 CAR-T cells against 4 different target cells by flow cytometry.1
Anti-CD38 CAR-T Cell Therapy Animal Models
Creative Biolabs offers a variety of animal models to assist clients’ projects, including cell line-derived xenografted (CDX) models, and patient-derived xenografted (PDX) models. At the same time, leveraging our years of experience in CART fields, we provide various optimal experiment schemes for customer reference.
Fig.9 Experimental design of in vivo anti-tumor assessment for CD38 CAR-T.1
Efficacy Test of Anti-CD38 CAR-T
Comprehensive efficacy test and toxicity evaluation services are also available in Creative Biolabs, please don't hesitate to reach out to us for further information and offerings regarding CD38 CAR-T services and products.
Fig.10 In vivo efficacy assessment of CD38 CAR-T in a mouse xenograft tumor model.1
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-0123-ZP639 | Anti-CD38 (026) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 026 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP641 | Anti-CD38 (OKT10) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | OKT10 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP1 | Anti-CD38 (38SB39 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 38SB39 | Humanized | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP2 | Anti-CD38 (Daratumumab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | Daratumumab | Human | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-LX197 | Anti-CD38 VHH(X3XH197) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH197 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX198 | Anti-CD38 VHH(X3XH198) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH198 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX199 | Anti-CD38 VHH(X3XH199) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH199 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX200 | Anti-CD38 VHH(X3XH200) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH200 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX201 | Anti-CD38 VHH(X3XH201) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH201 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX202 | Anti-CD38 VHH(X3XH202) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH202 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX203 | Anti-CD38 VHH(X3XH203) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH203 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX204 | Anti-CD38 VHH(X3XH204) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH204 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX562 | Anti-CD38 VHH(X3XH193) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH193 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX563 | Anti-CD38 VHH(X3XH194) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH194 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX564 | Anti-CD38 VHH(X3XH195) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH195 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX565 | Anti-CD38 VHH(X3XH196) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH196 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX566 | Anti-CD38 VHH(X3XH197) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH197 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX567 | Anti-CD38 VHH(X3XH198) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH198 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX568 | Anti-CD38 VHH(X3XH199) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH199 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX569 | Anti-CD38 VHH(X3XH200) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH200 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0823-LX18 | Anti-hCD38 (MAB) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | MAB | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
